Detalhe da pesquisa
1.
Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials.
Arthritis Rheum
; 65(6): 1586-91, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23529285
2.
Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.
Arthritis Rheum
; 64(11): 3660-5, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22806274
3.
First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.
Clin Transl Sci
; 14(4): 1314-1326, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33503289
4.
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.
Clin Pharmacol Ther
; 105(4): 1031-1039, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30402880
5.
Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.
Arthritis Res Ther
; 21(1): 216, 2019 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31647025
6.
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.
Arthritis Rheumatol
; 66(2): 379-89, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24504810
7.
Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.
J Clin Transl Hepatol
; 1(2): 116-24, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26357610